Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Polyacrylic acid of PAA have been prepared that are responsive to pH and temperature stimuli, demonstrating the possibility to be used for drug delivery purposes. ATRP has been used to growth PAA brushes from the surface. One reported approach was with surface-initiated ATRP of tert-butyl acrylate that was subsequently deprotected through pyrolysis to form the carboxylic acid. These PAA brushes can form chelate complex with silver and can therefore exhibit antibacterial activity. Polyacrylic acid Poly(acrylic acid) (PAA; trade name Carbomer) is a synthetic high-molecular weight polymers of acrylic acid. The IUPAC name is poly(1-carboxyethylene. They may be homopolymers of acrylic acid, or